As of the latest Form 4 filed Jun 8, 2026.
What Aclaris Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 13 most recent filings for ACRS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | 2026-06-05 | Humphries William D. Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-05 | Molineaux Christopher P. Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-05 | Mehra Anand Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-05 | GOWEN MAXINE Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-05 | MILANO VINCENT Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-05 | SCHIFF ANDREW N Director | MExercise | +11.6K | — | — | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Hall Jesse Wayne Chief Medical Officer | FTax | −9.33K | $4.41 | $41.1K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Hall Jesse Wayne, Chief Medical Officer | MExercise | +36.4K | — | — | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | Leonard Braden Michael 10% owner | SSale | −300K | $4.53 | $1.36M | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-01 | Balthaser Kevin Chief Financial Officer | FTax | −677.00 | $2.87 | $1.94K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-01 | Balthaser Kevin, Chief Financial Officer | MExercise | +2.38K | — | — | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Walker Neal INTERIM PRESIDENT AND CEO | FTax | −2.78K | $1.26 | $3.51K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Walker Neal, INTERIM PRESIDENT AND CEO | MExercise | +9.47K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ACRS’s full analysis or the market-wide insider trading feed. The tabs above jump to ACRS’s other SEC data.
Source: SEC Form 4 filings for ACRS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.